---
title: "Tesofensine"
slug: "tesofensine"
type: "compound"
category: "Body Composition"
url: "https://peptidesciencethailand.com/compounds/tesofensine"
description: "A triple monoamine reuptake inhibitor originally studied for neurodegeneration, now investigated for weight management. Clinical trial data and mechanism."
---
# Tesofensine

*Triple Monoamine Reuptake Inhibitor, Modulating Appetite and Metabolic Signaling*

**Category:** Body Composition  
**Format:** Capsules  
**Amount:** 250mcg x 60 capsules  
**Purity:** >99% (HPLC)

## Overview

Tesofensine is a small molecule triple monoamine reuptake inhibitor originally developed by NeuroSearch A/S (Denmark) as an investigational treatment for neurodegenerative conditions including Parkinson's disease and Alzheimer's disease. During Phase II clinical trials for these neurological indications, researchers observed consistent and significant body weight reduction in study participants, redirecting research interest toward its metabolic and appetite-regulatory properties. Tesofensine is not a peptide but a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), included in research compound libraries alongside peptides due to its relevance to body composition research.

The primary pharmacological mechanism of Tesofensine involves simultaneous inhibition of presynaptic reuptake transporters for three monoamine neurotransmitters: serotonin (5-HT), norepinephrine (NE), and dopamine (DA). By blocking the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT), Tesofensine increases synaptic concentrations of all three monoamines in brain regions controlling appetite, satiety, reward, and metabolic regulation. This triple reuptake inhibition profile distinguishes Tesofensine from selective serotonin reuptake inhibitors (SSRIs) or dual norepinephrine-dopamine reuptake inhibitors, which affect only one or two monoamine systems.

The appetite-suppressive effects of Tesofensine are mediated through convergent actions on hypothalamic feeding circuits. Elevated serotonin in the ventromedial hypothalamus activates 5-HT2C and 5-HT1B receptors on pro-opiomelanocortin (POMC) neurons, increasing melanocortin signaling that suppresses appetite through MC4R activation in the paraventricular nucleus. Simultaneously, increased norepinephrine in the lateral hypothalamus modulates orexinergic and neuropeptide Y (NPY) signaling, reducing hunger drive. Elevated dopamine in the nucleus accumbens and ventral tegmental area modulates the reward value of food, reducing hedonic eating behavior driven by the mesolimbic dopamine reward pathway.

Phase II clinical trial results, published by Astrup et al. (2008) in The Lancet, demonstrated dose-dependent weight loss in obese participants receiving Tesofensine at 0.25mg, 0.5mg, and 1.0mg daily for 24 weeks. The 0.5mg dose group achieved a mean body weight reduction of approximately 12.8 kg compared to 2.2 kg in the placebo group, with the 1.0mg group showing even greater reductions. Importantly, the weight loss was accompanied by improvements in waist circumference, plasma triglycerides, insulin sensitivity (HOMA-IR), and other cardiometabolic risk markers.

Beyond appetite suppression, Tesofensine appears to increase resting metabolic rate through norepinephrine-mediated sympathetic activation. Increased synaptic norepinephrine activates beta-adrenergic receptors on brown adipose tissue and skeletal muscle, stimulating thermogenesis and fatty acid oxidation. Clinical studies measuring resting energy expenditure found modest but statistically significant increases in metabolic rate in Tesofensine-treated participants compared to placebo, suggesting a dual mechanism combining reduced energy intake with enhanced energy expenditure.

The dopaminergic component of Tesofensine's mechanism has generated particular research interest regarding its effects on food reward processing and compulsive eating behavior. Neuroimaging studies have shown that enhanced dopaminergic signaling in the prefrontal cortex and striatum can improve executive control over food-related decision making, potentially reducing the impulsive eating patterns that undermine dietary adherence. This cognitive dimension of appetite regulation distinguishes Tesofensine from peripherally acting anti-obesity compounds that do not address the neurological drivers of overconsumption.

Pharmacologically, Tesofensine has a relatively long elimination half-life of approximately 8 to 9 days, enabling once-daily oral dosing. Steady-state plasma concentrations are achieved after approximately 6 to 8 weeks of daily administration. The compound is metabolized primarily by CYP3A4 and CYP2D6 hepatic cytochrome P450 enzymes, which has implications for drug-drug interactions with other medications metabolized through these pathways.

Cardiovascular safety has been a primary focus of Tesofensine clinical evaluation. The norepinephrine reuptake inhibition component produces measurable increases in heart rate and blood pressure in some individuals, effects that are dose-dependent and more pronounced at the 1.0mg dose level. Phase II trial data showed mean heart rate increases of 7.4 beats per minute at the 0.5mg dose, necessitating careful cardiovascular screening and monitoring during administration. These cardiovascular effects have influenced the dose selection for ongoing Phase III clinical evaluation, with the 0.5mg dose identified as the optimal balance between efficacy and cardiovascular tolerability.

Tesofensine is currently in Phase III clinical trials (as Tesomet, a combination with metoprolol) for obesity and Prader-Willi syndrome, being developed by Saniona. The compound has not yet received regulatory approval in any jurisdiction. Its pharmacological profile as a centrally-acting triple reuptake inhibitor requires comprehensive medical evaluation and monitoring, particularly regarding cardiovascular parameters, psychiatric history, and concurrent medication use.

## Mechanism of Action

### Step 1: Triple Monoamine Transporter Inhibition

Tesofensine binds to and inhibits the presynaptic serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT), preventing reuptake of these monoamines from the synaptic cleft and increasing their synaptic concentrations in brain feeding, reward, and metabolic control centers.

### Step 2: Hypothalamic Satiety Signaling Enhancement

Elevated serotonin in the ventromedial hypothalamus activates 5-HT2C and 5-HT1B receptors on POMC neurons, increasing alpha-MSH release and melanocortin signaling through MC4R in the paraventricular nucleus, promoting satiety and reducing appetite drive.

### Step 3: Noradrenergic Metabolic Activation

Increased norepinephrine activates beta-adrenergic receptors on brown adipose tissue and skeletal muscle, stimulating thermogenesis, fatty acid oxidation, and resting metabolic rate. In the lateral hypothalamus, norepinephrine modulates orexinergic signaling that governs hunger-wake coupling.

### Step 4: Dopaminergic Reward Modulation

Enhanced dopamine signaling in the nucleus accumbens and prefrontal cortex modulates the reward value of food and improves executive control over eating behavior, reducing hedonic eating driven by the mesolimbic reward pathway and strengthening cognitive regulation of food intake decisions.

### Step 5: Integrated Energy Balance Shift

The convergent effects of reduced appetite (serotonin), increased metabolic rate (norepinephrine), and normalized food reward processing (dopamine) produce a sustained negative energy balance, resulting in progressive reductions in body weight and adipose tissue mass over weeks to months of administration.

## Researched Benefits

### Clinically Demonstrated Weight Reduction

Phase II clinical trials published in The Lancet documented dose-dependent weight loss of up to 12.8 kg over 24 weeks at the 0.5mg dose, significantly exceeding placebo response. This weight loss was accompanied by improvements in waist circumference, plasma triglycerides, and insulin sensitivity markers.

### Appetite Regulation Through Central Mechanisms

Tesofensine's triple reuptake inhibition addresses appetite regulation through convergent serotonergic satiety signaling, noradrenergic hunger modulation, and dopaminergic reward normalization. This multi-pathway central mechanism provides comprehensive appetite regulation rather than targeting a single neurotransmitter system.

### Metabolic Rate Enhancement

Beyond appetite suppression, Tesofensine's noradrenergic component increases resting metabolic rate through beta-adrenergic activation of thermogenic pathways in brown adipose tissue and skeletal muscle. Clinical measurements confirmed statistically significant increases in resting energy expenditure during Tesofensine administration.

### Cardiometabolic Risk Factor Improvement

Clinical trial participants demonstrated improvements in multiple cardiometabolic markers beyond weight loss alone, including reductions in plasma triglycerides, improvements in insulin sensitivity (HOMA-IR), and reductions in waist circumference, suggesting beneficial metabolic effects independent of weight change alone.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 0.25-0.5mg per day orally, based on Phase II clinical trial dosing |
| Route | Oral administration (capsule) |
| Duration | Clinical trials evaluated 24-week administration periods |
| Cycle Notes | Due to Tesofensine's long elimination half-life (approximately 8-9 days), steady-state plasma concentrations require 6-8 weeks to achieve. Discontinuation effects may persist for several weeks due to this extended half-life. Clinical protocols have not established standard cycling recommendations. |
| Reconstitution | Oral capsule formulation, no reconstitution required. Store in a cool, dry place protected from light and moisture. |

> **Specialist note:** A your specialist must conduct comprehensive cardiovascular screening including baseline heart rate, blood pressure, and ECG evaluation before initiating Tesofensine. Due to its monoamine reuptake inhibition mechanism, thorough psychiatric history assessment is essential, as is evaluation of all concurrent medications for potential interactions through CYP3A4 and CYP2D6 metabolic pathways.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Oral Capsules |
| Amount | 250mcg x 60 capsules |
| Purity | >99% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Composition | Tesofensine hydrochloride (small molecule, not a peptide) |
| Molecular Weight | 399.87 g/mol (hydrochloride salt) |
| Storage | Store at room temperature (15-25C) in a cool, dry place protected from light and moisture. |
| Appearance | White to off-white crystalline powder in capsule form |

## Medical Guidance

Tesofensine is a centrally-acting triple monoamine reuptake inhibitor with direct effects on cardiovascular function (heart rate, blood pressure) through noradrenergic activation. Comprehensive cardiovascular evaluation including baseline ECG is essential before initiation. The compound's psychiatric implications (monoamine modulation) require thorough mental health history assessment. Drug-drug interactions through CYP3A4 and CYP2D6 pathways must be evaluated. Individuals with cardiovascular disease, uncontrolled hypertension, psychiatric conditions, or those taking monoamine-affecting medications require especially careful specialist assessment.

## Frequently Asked Questions

### Is Tesofensine a peptide?

No. Tesofensine is a small molecule triple monoamine reuptake inhibitor, not a peptide. It is a synthetic pharmaceutical compound originally developed for neurological conditions. It is included in research compound collections alongside peptides because of its relevance to body composition and metabolic research. Its mechanism of action (neurotransmitter reuptake inhibition) is fundamentally different from peptide-receptor interactions.

### How does Tesofensine differ from other weight management compounds?

Tesofensine simultaneously inhibits reuptake of three monoamines (serotonin, norepinephrine, and dopamine), addressing appetite, metabolic rate, and food reward processing through convergent central mechanisms. Most other centrally-acting compounds target only one or two neurotransmitter systems. Additionally, Tesofensine combines appetite reduction with increased resting metabolic rate, providing dual mechanisms for negative energy balance.

### What were the results of Tesofensine clinical trials?

Phase II clinical trials published in The Lancet (Astrup et al., 2008) showed dose-dependent weight loss in obese participants. The 0.5mg daily dose group lost approximately 12.8 kg over 24 weeks versus 2.2 kg in the placebo group. Weight loss was accompanied by improvements in waist circumference, triglycerides, and insulin sensitivity. Phase III trials are currently ongoing.

### What cardiovascular monitoring is required with Tesofensine?

Due to norepinephrine reuptake inhibition, Tesofensine can increase heart rate and blood pressure. Phase II data showed mean heart rate increases of approximately 7.4 beats per minute at the 0.5mg dose. A specialist must evaluate baseline cardiovascular status including resting heart rate, blood pressure, and ECG before initiation, with regular monitoring throughout administration.

### Is medical supervision necessary for Tesofensine?

Yes, absolutely. Tesofensine is a centrally-acting compound that modulates monoamine neurotransmitter systems with direct cardiovascular and psychiatric implications. A specialist must assess cardiovascular health, psychiatric history, all concurrent medications (particularly CYP3A4/CYP2D6 substrates and other monoamine-affecting drugs), and establish baseline monitoring parameters before initiating any protocol. Ongoing medical supervision is essential throughout use.

## Related Compounds

- /compounds/aod-9604
- /compounds/tesamorelin
- /compounds/5-amino-1mq